Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T17:02:13.461Z.
Calculation as of: 2026-10-06T17:02:13.461Z.
Quote observation: 2026-10-06T17:00:52.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 31946573a42b73cd13b381604bc2f467f5098c78190e00cee0d2639f3054c777
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
4D Molecular Therapeutics, Inc.
Market Cap
$665.51M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$668.57M
Operating Cash Flow Yield
6.90%
TTM Avg
9.30%
3Y Avg
5.99%
5Y Avg
5.99%
Market Cap
$660.39M
Operating Cash Flow Yield
0.05%
TTM Avg
0.05%
3Y Avg
0.05%
5Y Avg
0.05%
Market Cap
$673.15M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$681.76M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$649.48M
Operating Cash Flow Yield
N/A
TTM Avg
2.08%
3Y Avg
1.21%
5Y Avg
1.21%
Market Cap
$688.65M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$632.99M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 4D Molecular Therapeutics, Inc. (FDMT) | $665.51M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $668.57M | 6.90% | 9.30% | 5.99% | 5.99% |
| Starling Oncology, Inc. (STLN)vs › | $660.39M | 0.05% | 0.05% | 0.05% | 0.05% |
| Helus Pharma Inc. (HELP)vs › | $673.15M | N/A | N/A | N/A | N/A |
| Annexon, Inc. (ANNX)vs › | $674.61M | N/A | N/A | N/A | N/A |
| Solid Biosciences Inc. (SLDB)vs › | $681.76M | N/A | N/A | N/A | N/A |
| OmniAb, Inc. (OABI)vs › | $649.48M | N/A | 2.08% | 1.21% | 1.21% |
| Anteris Technologies Global Corp. (AVR)vs › | $688.65M | N/A | N/A | N/A | N/A |
| SOPHiA GENETICS S.A. (SOPH)vs › | $632.99M | N/A | N/A | N/A | N/A |
| Aura Biosciences, Inc. (AURA)vs › | $632.00M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
